Celadon Pharmaceuticals PLC Cash Flow Conversion Efficiency
Celadon Pharmaceuticals PLC cash flow conversion efficiency. Based on the latest financial reports, Celadon Pharmaceuticals PLC (CEL) has a cash flow conversion efficiency ratio of -0.525x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.29 Million ≈ $-156.59 USD) by net assets (GBX2.45 Million ≈ $298.46 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Celadon Pharmaceuticals PLC (2019–2023)
Cash flow conversion efficiency of Celadon Pharmaceuticals PLC from 2019 to 2023. This chart illustrates how Celadon Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Celadon Pharmaceuticals PLC (CEL) share price today for real-time trading data and today's change.
Celadon Pharmaceuticals PLC Cash Flow Conversion Ratio Explained
Celadon Pharmaceuticals PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Celadon Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celadon Pharmaceuticals PLC ranked by their cash flow conversion efficiency. Also see CEL market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lexington Gold Ltd
LSE:LEX
|
-0.028x |
|
Axa Property Trust
LSE:WINV
|
0.011x |
|
FOXO Technologies Inc.
NYSE MKT:FOXO
|
-0.060x |
|
Greiffenberger AG
F:GRF
|
0.089x |
|
Gunsynd PLC
LSE:GUN
|
-0.112x |
|
Slate Grocery REIT
TO:SGR-U
|
0.025x |
|
Cirata plc
LSE:CRTA
|
-0.218x |
|
Rockfire Resources plc
LSE:ROCK
|
-0.092x |
Annual Cash Flow Conversion Efficiency for Celadon Pharmaceuticals PLC (2019–2023)
The table below shows the annual cash flow conversion efficiency of Celadon Pharmaceuticals PLC from 2019 to 2023. Review how much free cash does Celadon Pharmaceuticals PLC generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | GBX3.18 Million ≈ $387.04 |
GBX-5.97 Million ≈ $-726.62 |
-1.877x | -116.58% |
| 2022-12-31 | GBX7.04 Million ≈ $856.20 |
GBX-6.10 Million ≈ $-742.19 |
-0.867x | -76.53% |
| 2021-12-31 | GBX6.41 Million ≈ $780.00 |
GBX-3.15 Million ≈ $-383.02 |
-0.491x | +37.31% |
| 2020-12-31 | GBX99.03K ≈ $12.05 |
GBX-77.57K ≈ $-9.44 |
-0.783x | -4386.83% |
| 2019-12-31 | GBX-113.47K ≈ $-13.81 |
GBX1.98K ≈ $0.24 |
-0.017x | -- |
About Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.